XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Company Operations by Product
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Company Revenue by Product
Company Revenue by Product 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total revenues by these products: 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Revenues by Product:
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Bloxiverz
 
$
3,656

 
$
9,920

 
$
16,691

 
$
37,541

Vazculep
 
8,759

 
9,573

 
33,097

 
29,906

Akovaz
 
5,991

 
18,561

 
28,083

 
65,110

Noctiva
 
1,047

 
—

 
2,002

 
—

Other
 
373

 
1,093

 
2,230

 
5,452

Total product sales
 
19,826

 
39,147

 
82,103

 
138,009

License revenue
 
—

 
528

 
246

 
484

Total revenues
 
$
19,826

 
$
39,675

 
$
82,349

 
$
138,493